首页 > 文献资料
-
Objective:To explore the influence of inflammation factors and intestinal mucosal barrier function on severe acute pancreatitis patients treated with bifidobacterium triple viable capsules.Methods:88 cases severe acute pancreatitis patients were divided into observation group and control group according to admission order, 44 cases in each group, all patients were given conventional treatment, on this base, patients in observation group were treated by oral bifidobacterium triple viable capsules, they were treated for one week, detected the serum inflammatory factors: the tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and C-reactive protein (CRP) and intestinal mucosal barrier function index: endotoxin, diamine oxidase (DAO), D-lactic acid, urinary lactulose/mannitol (L/M) in the two groups before and after treatment.Results:The levels of TNF-α, IL-6 and CRP in two groups after treatment were significantly reduced than before treatment, and after treatment the levels of TNF-α, IL-6 and CRP in observation group was significantly lower than that of the control group, all the difference was statistically significant; The levels of endotoxin, DA, D-lactic acid, L/M in two groups after treatment were significantly reduced than before treatment, and the levels of endotoxin, DA, D-lactic acid,L/M after treatment in observation group was significantly lower than that of the control group, the difference was statistically significant.Conclusion: Based on conventional treatment combined bifidobacterium triple viable capsules can significantly reduce inflammation in patients with severe acute pancreatitis, it can protect the intestinal mucosal barrier function, and has important clinical significance.
